NCT00402506View on ClinicalTrials.gov

A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG

PHASE3CompletedINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

November 30, 2006

Study Completion Date

September 30, 2007

Conditions
Coronary Artery Bypass Graft SurgeryMyocardial IschemiaReperfusion Injury
Interventions
DRUG

(MC-1) Pyridoxal 5'-phosphate

Trial Locations (2)

27705

Duke Clinical Research Institute, Durham

H1T 1C8

Montreal Heart Institute, Montreal

Sponsors

Lead Sponsor

Medicure
All Listed Sponsors
lead

Medicure

INDUSTRY

NCT00402506 - A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG | Biotech Hunter | Biotech Hunter